Impact of the introduction of A/Sydney/5/97 H3N2 influenza virus into South Africa

Journal of Medical Virology

Volumn 59, Issue 4, 1999, Pages 561-568

  Besselaar, Terry G ^a   Schoub, Barry D ^b   Blackburn, Nigel K ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b NONE

Author keywords

Disease; Epidemic; Epidemiology; Hemagglutinin; Vaccine

Indexed keywords

ABSENTEEISM; ARTICLE; EPIDEMIC; HUMAN; INFECTION SENSITIVITY; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; SOUTH AFRICA; VIRUS DETECTION; VIRUS ISOLATION; VIRUS TYPING;

ABSENTEEISM; AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; COMMON COLD; COUGH; DISEASE OUTBREAKS; DRUGS, NON-PRESCRIPTION; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA;

EID: 0032742705     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199912)59:4<561::AID-JMV22>3.0.CO;2-5     Document Type: Article

References (17)

1. National Institute for Virology. 1994-1997. Annual Reports. Johannesburg, South Africa: National Institute for Virology.
2. Anonymous. 1996. Geography and Climate: RSA Statistics in Brief. Pretoria: Central Statistics Services, p 1.
3. Anonymous. 1998. Drug alert: recommendations pertaining to the use of viral vaccines: influenza. South African Med J 88:169.
4. Assaad F, Cockburn WC, Sundaresan TK. 1973. Use of excess mortality from respiratory diseases in the study of influenza. Bull World Health Org 49:219-233.
5. Australian Influenza Vaccine Committee. 1997. Minutes of the Annual Meeting Held on October 10, 1997. Canberra: TGA Laboratories.
6. Besselaar TG, Blackburn NK, Schoub BD. 1996. The molecular characterization of influenza virus strains isolated in South Africa during 1993 and 1994. Res Virol 147:239-245.
7. Centers for Disease Control. 1998. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practises (ACIP). Morbid Mortal Weekly Report 47:1-26.
8. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer SP, Wright PF. 1994. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Inf Dis 169:68-76.
9. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. 1995. The efficacy of influenza vaccine in elderly persons. Ann Int Med 123:518-527.
10. Hampson AW, Gust ID. 1997. Preliminary Data for Influenza Vaccine Formulation Decision 1997. Melbourne: WHO Collaborating Centre for Influenza.
11. Hay AJ, Pu Lin Y, Cameron KR, Gregory V. 1998. Annual Report. London: WHO Collaborating Centre for Influenza.
12. McAnerney JM, Johnson S, Schoub BD. 1994. Surveillance of respiratory viruses: a 10-year laboratory-based study. South African Med J 84:473-477.
13. Rota PA, Hemphill ML, Whistler T, Regnery HL, Kendal AP. 1992. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 73: 2737-2742.
14. Schoub BD, Johnson S, McAnerney JM, Martin E, Dos Santos IL. 1986. Laboratory studies of the 1984 influenza epidemic on the Witwatersrand. South African Med J 70:815-818.
15. Schoub BD, Johnson S, McAnerney JM, Blackburn NK. 1994. Benefits and limitations of the Witwatersrand influenza and acute respiratory infections surveillance programme. South African Med J 84:674-678.
16. Verhoeyen M, Fang R, Min Jou W, Devos R, Huylebroeck D, Saman E, Fiers W. 1980. Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature 286:771-776.
17. Wiley DC, Skehel JJ. 1987. The structure and function of the haemagglutinin membrane glycoprotein of influenza virus. Ann Rev Biochem 56:365-394.